==== Front Sci Rep Sci Rep Scientific Reports 2045-2322 Nature Publishing Group UK London 37584 10.1038/s41598-023-37584-1 Article Long-term surveillance provides real-world evidences of safety and effectiveness in intravitreal aflibercept treatment for age-related macular degeneration https://orcid.org/0000-0003-4797-5705 Ozawa Yoko ozawa@a5.keio.jp yoko.ozawa@fujita-hu.ac.jp 1234 Ohgami Kazuhiro 5 Sasaki Koji 5 Hirano Kazufumi 5 Sunaya Toshiyuki 6 1 grid.256115.4 0000 0004 1761 798X Department of Clinical Regenerative Medicine Eye Center, Fujita Medical Innovation Center Tokyo, Fujita Health University School of Medicine, Tokyo, Japan 2 grid.430395.8 Department of Ophthalmology, St. Luke’s International Hospital, Tokyo, Japan 3 grid.419588.9 0000 0001 0318 6320 Department of Ophthalmology, St. Luke’s International University, Tokyo, Japan 4 grid.26091.3c 0000 0004 1936 9959 Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan 5 Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan 6 grid.419082.6 0000 0004 1754 9200 Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan 30 6 2023 30 6 2023 2023 13 1059724 1 2023 23 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. This prospective, multicentre, postmarketing surveillance were conducted to report on the long-term safety and effectiveness of intravitreal aflibercept (IVT-AFL) treatment in clinical practice of Japanese patients with neovascular age-related macular degeneration (nAMD) who newly initiated IVT-AFL treatment. The primary outcomes were the incidence of adverse events (AEs) and of adverse drug reactions (ADRs) over 36 months. Number of injections, timing of ADR occurrence, and some effectiveness index were also summarised. A total of 3,872 patients received 7.2 ± 5.8 (mean ± standard deviation) injections, and AEs occurred in 5.73% of patients. ADRs were reported in 2.76% of patients, with ocular and nonocular ADRs in 2.07% and 0.72% of patients, respectively. Most vitreo-retinal events developed within 6 months of initial IVT-AFL treatment, and most instances of increased intraocular pressure and cerebral infarction developed after 6 months of follow-up. Mean best-corrected visual acuity and central retinal thickness were numerically better throughout the follow-up period compared with baseline. These results indicated acceptable tolerability and effectiveness of IVT-AFL treatment in patients with nAMD in clinical practice in Japan. Information regarding the risk and the timing of ADRs is valuable for safe and effective long-term treatment of patients with nAMD. Trial registration number: NCT01756248. Subject terms Retinal diseases Medical research issue-copyright-statement© Springer Nature Limited 2023 ==== Body pmcIntroduction Age-related macular degeneration (AMD) is one of the leading causes of vision impairment in adults aged 50 years or older worldwide1. The prevalence of AMD in the Japanese population aged 40 years or older is reported to be 1.2% and is increasing2,3. The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has greatly improved the visual prognosis in eyes with neovascular AMD (nAMD); however, this chronic and progressive disease is still an important cause of visual impairment in recently ageing societies1,4. Aflibercept (Eylea, Regeneron, Tarrytown, NY, and Bayer HealthCare, Berlin, Germany) is an anti-VEGF agent that has high binding affinity to VEGF-A and can also bind to VEGF-B and placental growth factor5. Following confirmation of the clinical efficacy and safety of intravitreal aflibercept (IVT-AFL) treatment in patients with nAMD in two Phase III trials, VIEW 1 and 26,7, IVT-AFL treatment has been extended to more diverse populations than in the VIEW trials, such as patients who have better best-corrected visual acuity (BCVA) at baseline8,9, and to longer treatment periods. Accordingly, the long-term safety and effectiveness of this treatment should be evaluated in a large cohort from routine clinical practice. Based on the results from the VIEW trials6,7, the Japan risk management plan (RMP) identified some ocular events as ‘important risks’ and arterial thromboembolic events (ATEs) as ‘important potential risks’ that may occur during IVT-AFL treatment (supplemental Table 1)10. In addition, intraocular inflammation has been reported as an adverse drug reaction (ADR) of some intravitreal anti-VEGF agents11–14.Table 1 Patient characteristics at baseline. Safety analysis set (n = 3,872) Male sex, n (%) 2,650 (68.4) Age, years Mean ± SD (range) 74.3 ± 8.9 (24–97)  < 40, n (%) 3 (0.1) 40–49, n (%) 24 (0.6) 50–59, n (%) 201 (5.2) 60–69, n (%) 808 (20.9) 70–79, n (%) 1,696 (43.8) 80–89, n (%) 1,060 (27.4)  ≥ 90, n (%) 80 (2.1) nAMD subtype*, n (%) tAMD 1,839 (47.5) PCV 1,564 (40.4) RAP 141 (3.6) Types of CNV lesions on FA*, n (%) Occult CNV 1,228 (31.7) Predominantly classic CNV 670 (17.3) Minimally classic CNV 404 (10.4) Other or unknown 1,576 (40.7) Duration of disease from onset to first IVT-AFL, months Mean ± SD (range) 23.2 ± 32.6 (0–360)  < 2, n (%) 324 (8.4)  ≥ 2, < 6, n (%) 290 (7.5)  ≥ 6, < 12, n (%) 173 (4.5)  ≥ 12, n (%) 747 (19.3) Unknown 2,338 (60.4) Best-corrected visual acuity, logMAR, n (%)  < 0.301 1,614 (41.7)  ≥ 0.301 2,238 (57.8) Best-corrected visual acuity, logMAR, n (%)  ≤ 0.155 1,290 (33.3)  > 0.155 2,562 (66.2) *Including overlap. CNV Choroidal neovascularization, FA Fluorescein angiography, IVT-AFL Intravitreal aflibercept, nAMD Neovascular age-related macular degeneration, PCV Polypoidal choroidal vasculopathy, RAP Retinal angiomatous proliferation, SD Standard deviation, tAMD Typical age-related macular degeneration. In this study, we report on prospective observational surveillance that was performed to evaluate the safety profile and effectiveness of IVT-AFL treatment in patients with nAMD during 36 months of follow-up in Japan. Patient selection and treatment regimen were determined by the treating clinician. Thus, the results reflect those of routine clinical practice in Japan and may be informative for clinicians for the safe and effective management of patients over longer time periods. Results Patient population A total of 4,428 patients who newly initiated IVT-AFL treatment (with or without prior treatments other than IVT-AFL) for nAMD were enrolled, of which 3,872 were included in the safety analysis set (SAF) and 3,684 in the effectiveness analysis set (EAS) (supplemental Figure 1).Figure 1 Timing of onset of ADRs. The number of patients who developed each ADR are shown for each period of + 30 days from the first date of IVT-AFL, + 31 to + 60 days, + 61 to + 90 days, + 91 to + 180 days, + 181 to + 360 days, + 361 to + 720 days, and + 721 to + 1,080 days. The period of any prior treatment was not considered. ADR adverse drug reaction, IVT-AFL intravitreal aflibercept. Baseline characteristics of the 3,872 patients in the SAF are shown in Table 1. Age was 74.3 ± 8.9 (mean ± SD, range 24–97) years, with 2,836 patients (73.2%) aged 70 years or older, and 2,650 patients (68.4%) were male. Overall, 1,564 patients (40.4%) had polypoidal choroidal vasculopathy (PCV), and 41.7% of patients had baseline BCVA better than 0.301 logMAR (20/40 in Snellen’s chart, which was the upper boundary value for inclusion criteria in the VIEW trials) and 33.3% had baseline BCVA better than 0.155 logMAR (20/30 in Snellen’s chart, which is the visual acuity required to obtain a driver’s license in Japan). In the SAF, 1,309 patients (33.8%) had at least 1 ocular comorbidity at baseline, such as cataract (27.6%), glaucoma (4.0%), or conjunctivitis (2.6%), and 1,391 (35.9%) patients had at least 1 nonocular comorbidity, such as hypertension (24.3%), diabetes mellitus (8.5%), or dyslipidaemia (6.1%) (supplemental Table 2).Table 2 Incidence of ocular and nonocular adverse events and adverse drug reactions. Safety analysis set (n = 3,872) Patients, n (%) AE SAE ADR SADR Total events 222 (5.73) 94 (2.43) 107 (2.76) 44 (1.14) Ocular event 159 (4.11) 45 (1.16) 80 (2.07) 23 (0.59) Nonocular event 70 (1.81) 50 (1.29) 28 (0.72) 21 (0.54) AE Adverse event, ADR Adverse drug reaction, SADR Serious adverse drug reaction, SAE Serious adverse event. In the SAF, 1,222 patients (31.6%) had a history of at least 1 ocular medical condition, such as cataract (26.8%), and 890 patients (23.0%) had a history of at least 1 nonocular medical condition, such as hypertension (8.4%) (Supplemental Table 3). In addition, 2,519 patients (65.1%) had not been previously treated for nAMD (treatment-naïve patients) and 1,281 patients (33.1%) had been previously treated for nAMD with agents other than IVT-AFL (treatment-switched patients). Of the 1,281 treatment-switched patients, 1,077 (84.1%) had received intravitreal anti-VEGF agents other than IVT-AFL (95.6% of whom had received ranibizumab) and 322 (25.1%) had received photodynamic therapy. The most common reason for switching to IVT-AFL from other anti-VEGF agents was lack of effectiveness (882 patients, 81.9%).Table 3 Incidence of important safety specifications. Safety analysis set (n = 3,872) Patients, n (%) Adverse event Adverse drug reaction Nonserious Serious Nonserious Serious Important risks identified Inflammatory intraocular response 1 (0.03) 0 (0.00) 1 (0.03) 0 (0.00) Increased intraocular pressure 20 (0.52) 2 (0.05) 15 (0.39) 1 (0.03) Retinal tear and retinal detachment 6 (0.15) 2 (0.05) 5 (0.13) 1 (0.03) Traumatic cataract 1 (0.03) 1 (0.03) 0 (0.00) 1 (0.03) Important potential risk Arterial thromboembolic events 0 (0.00) 17 (0.44) 0 (0.00) 15 (0.39) Safety outcomes Treatment status In the SAF (n = 3,872), the observation period was 801.7 ± 412.5 (median: 1,035; range: 1–2,044) days. The number of injections through month 36 was 7.1 ± 5.8, the mode of the total number of injections was 3, which accounted for 22.2% of cases (n = 861). The number of injections was similar between the treatment-naïve (7.0 ± 5.5) and treatment-switched (7.5 ± 6.2) patients. The number of patients with concomitant therapy during the 36-month follow-up period was 293 (7.6%), of which 134 (3.5%) received photodynamic therapy. Ocular and nonocular safety events during 36-month follow-up Adverse events (AEs) occurred in 222 patients (5.73%) over the 36 months, with ocular AEs and nonocular AEs occurring in 159 (4.11%) and 70 (1.81%) patients, respectively. Among the AEs, ADRs were reported in 107 patients (2.76%), with ocular ADRs in 80 (2.07%) and nonocular ADRs in 28 (0.72%) patients (Table 2). The incidence of each safety event is shown in supplemental Table 4. Prespecified safety specifications related to IVT-AFL treatment One case (0.03%) of intraocular inflammatory response judged to be ADR was iritis (nonserious), which developed on day 2 of the second IVT-AFL treatment in a 58-year-old male patient (Table 3). This patient received a single treatment of bromfenac sodium hydrate and cefmenoxime hydrochloride and iritis resolved on day 12. ADRs of either ocular hypertension (OH) or increased intraocular pressure (IOP) were reported in 7 (0.18%) and 11 (0.28%) of patients, respectively, and 2 patients (0.05%) experienced both events (Table 3, Supplemental Table 4). Among patients with recorded IOP (n = 2,917), a greater proportion of patients with the comorbidity or medical history of glaucoma and/or OH experienced an increase in IOP of at least 10 mm Hg from baseline, compared with eyes without such comorbidity or medical history (23/206 [11.17%] and 88/2,711 [3.25%], respectively). The proportion of eyes with IOP elevated to above 20 mm Hg was also greater in those with such comorbidity or medical history (45/206, 21.84%) compared to those without (260/2,711 [9.59%]). ATEs as important ADRs were reported in 15 patients (0.39%, Table 3), cerebrovascular infarction in 9 patients (0.23%), myocardial infraction in 3 patients (0.08%), and cerebral infarction, lacunar infraction, and amaurosis fugax in 1 patient each (0.03%). All 15 patients who experienced ATEs as ADRs were aged 65 years or older. Of these, 5 patients had comorbidity (hypertension, diabetes mellitus, and/or hyperlipidaemia). Among those who developed ATEs, including both as ADRs and AEs, 16 patients (94.1%) did not have any medical history of ATEs. Outcomes of death judged to be ADR-related were reported in 5 patients (3 cases of death, 1 case of cardiac death and 1 case of cardiac disorder; Supplemental Table 4): an 83-year-old man with a history of hypertension, an 83-year-old woman with comorbid renal dysfunction and diabetes (in these 2 cases, the number of days between last IVT-AFL treatment and death was unknown), a 63-year-old man without comorbidities (died 234th day from last IVT-AFL treatment), an 86-year-old man with comorbidities including diabetes (died due to sudden cardiac death 10th day from last IVT-AFL treatment) and a 66-year-old man with comorbidities of angina pectoris and atrial fibrillation (died due to cardiac disorder 9th day from first IVT-AFL treatment). No patients were found to be pregnant during IVT-AFL treatment, and thus no embryotoxic or fetotoxic events were reported. Duration from initial IVT-AFL treatment to onset of ADR The timing of onset of major ADRs from the initial IVT-AFL treatment are shown in Fig. 1; not only ADRs classified as “important risks” but those occurring in 0.1% of patients or more are shown. All cases of retinal pigment epithelial (RPE) tear (7 patients [100%]) and macular hole (3 patients [100%]) and most cases of retinal haemorrhage (6/7 patients [85.7%]) and vitreous haemorrhage (3/4 patients [75.0%]) occurred within 6 months of initial treatment, whereas all cases of retinal tear (2 patients [100%]) and most cases of cataract (14/16 patients [87.5%]), OH (5/7 patients [71.4%]), and increased IOP (8/11 patients [72.7%]) developed between 6 and 36 months. As for systemic ADRs, most cases of cerebral infarction (6/9 patients [66.7%]) occurred between 6 and 36 months after initial IVT-AFL treatment. All cases of myocardial infarction (3 patients) occurred between 3 and 6 months. Reasons for treatment discontinuation In the SAF, the treatment retention rates at 12, 24, and 36 months were 78.4%, 66.0%, and 52.9%, respectively. The main reasons for treatment discontinuation over the 36 months were achievement of treatment goal (504 patients, 27.6%), loss of visit (492 patients, 27.0%), and referral to another hospital (423 patients, 23.2%). AEs accounted for 2.5% of the reasons for treatment discontinuation (Supplemental Table 5). Effectiveness outcomes The number of injections through month 36 was 7.3 ± 5.8, 7.2 ± 5.5, and 7.7 ± 6.2 for all patients in the EAS (n = 3,684), treatment-naïve patients (n = 2,393), and treatment-switched patients (n = 1,232), respectively. By the end of the study period, 1,697 patients (46.1%) in the EAS had discontinued the treatment. Mean BCVA and central retinal thickness (CRT) numerically improved over the 36 months compared with baseline (Fig. 2a,b), and similar trends were observed in the last observation carried forward (LOCF) analysis (supplemental Figure 2a and b). Although CRT was comparable between treatment-naïve and treatment-switched patients, BCVA was better in the treatment-naïve patients at every time point (Fig. 2c,d, supplemental Figure 2c and d).Figure 2 Changes in observed logMAR BCVA and CRT over the 36-month study period in all patients with nAMD (a and b, respectively) and in the treatment-naïve and treatment-switched subgroups (c and d) after starting IVT-AFL treatment. Data shown are mean values. BCVA best-corrected visual acuity, BL baseline, CRT central retinal thickness, IVT-AFL intravitreal aflibercept, logMAR logarithm of the minimum angle of resolution, SE standard error. Discussion This regulatory postmarketing surveillance study conducted in Japan was a large-scale, prospective, 36-month, observational study of 3,872 patients with nAMD who newly started IVT-AFL treatment that was designed to investigate the safety profile and effectiveness in clinical practice. The mean number of injections over the 36 months was lower than that of the 2-year results of the VIEW trials7. The safety findings were consistent with the known safety profile of IVT-AFL treatment in patients with nAMD in interventional studies7,15,16 and in long-term (24–48 months) observational studies8,17,18, and no new or unexpected safety signals were observed. Patients were predominantly male (68.4%) and 40.4% had PCV, which was comparable to previous reports from Japan2,3,19,20. As many as 41.7% of patients had a baseline BCVA better than 0.301 logMAR. In this surveillance, 73.2% of the patients were aged 70 years or older, which is consistent with the prevalence of nAMD stratified by age group in Japan and other Asian countries2,21, suggesting that older adults actively received IVT-AFL treatment. As a whole, these patient baseline characteristics generally reflect those in clinical practice in Japan during the periods of enrolment of 2012–2015, as supported by recent reports22,23. In this study, 1 case of nonserious intraocular inflammatory response was reported. This incidence of 0.03% is consistent with previous reports of IVT-AFL treatment7,13,15,16,24,25. Increased IOP after intravitreal anti-VEGF injection is a potential effect26. The incidence of OH and increased IOP in this cohort was 0.52% (Table 3) and is comparable to that reported previously7. Also, increased IOP was more likely develop during IVT-AFL treatment in eyes with comorbidities or medical history of glaucoma or OH27. This suggests that eyes with glaucoma or OH may be more susceptible to increased IOP following intravitreal anti-VEGF injection and that VEGF suppression might affect the trabecular meshwork function. It is reported in mice that VEGF is a paracrine regulator of the outflow facility of the trabecular meshwork28. Increased IOP events were observed primarily between 6 to 36 months of surveillance, suggesting that meticulous observation of IOP should occur with long-term treatment, particularly for eyes with glaucoma or OH. Regarding systemic safety, despite the longer observation period, the incidence of ATEs was below or comparable to that reported in previous prospective trials (0.9–3.6% over 2 years)7,15,16 or in a population-based retrospective study among patients who received intravitreal injections of ranibizumab or aflibercept (72.75 ATEs per 1,000 person-years)29. Of note, among those who developed ATEs, 16 patients (94.1%) did not have any medical history of ATEs. These results suggest the need for careful observation regardless of the presence or absence of a medical history of ATEs. Moreover, this surveillance study provides important findings about the timing of ADR occurrence in relation to the start of initial treatment, although some events were not included in the prespecified important safety specification (Table 3). RPE tear, macular hole, and retinal or vitreous haemorrhage were more likely to develop within 6 months. A previous study reported that approximately 70% of RPE tears developed within 6 months of initial treatment30. RPE tear30,31 and macular hole32 after intravitreal anti-VEGF treatment may be secondary to choroidal neovascular membrane contraction, which can occur relatively early. In contrast, most cases of cataract, OH, increased IOP, and cerebral infarction occurred between 6 and 36 months in the present study. The case of cataracts increased extremely after 12 months; it is possible that cataract surgery was performed at a time when nAMD had improved and stabilized after 12 months of treatment, given that 27.6% of patients had cataract at baseline (Supplemental Table 2) and that cataract surgery has been reported to exacerbate nAMD33. These results can help to inform both physicians and patients about safety issues in the long-term management of nAMD. Regarding effectiveness, anatomical outcomes improved in both the treatment-naïve and treatment-switched cohorts, while functional outcomes improved in the treatment-naïve cohort only, which is consistent with previous reports34,35. Patients with baseline BCVA better than 0.301 logMAR accounted for 41.7% of cases, and most had BCVA 0.152 logMAR or better. Thus, the ceiling effect may have impacted the observed change in BCVA. Nevertheless, BCVA improvement was observed, particularly in the treatment-naïve patients, consistent with that reported in previous studies of patients with relatively good baseline BCVA who received IVT-AFL treatment8,9. Although the current study was at clinical setting and the treatment protocol was not stipulated, the long-term effectiveness data was consistent with the previous data in which the treatment protocol was well-controled36,37. Approximately half of all patients discontinued follow-up before 36 months, suggesting that it is challenging to maintain long-term treatment in clinical practice. However, the most common reason for treatment discontinuation was achievement of the treatment goal (27.6%), and insufficient effect of treatment and experiencing an adverse event accounted for only 7.4% and 2.5% of discontinuations, respectively. Those patients who discontinued treatment due to ‘loss of visit’ or ‘were referred to another hospital’ may have included both improved and worsened patients, while many of the patients who returned to the original clinics would have achieved a treatment goal with stabilized nAMD conditions, given that all the treating clinicians in the surveillance sites were retina specialists or those who were conducted by them. Most patients discontinued follow-up for relatively positive reasons, nevertheless, clinicians should strongly recommend that even these patients continue follow-up visits for early detection of recurrence and for avoiding undertreatment. The strength of this study was the design, including its 36-month, multicentre, observational, prospective nature with 3,872 patients with nAMD newly starting IVT-AFL treatment. However, there are also some important limitations. First, diagnosis and treatment decisions were left to the clinicians’ discretion, which means we cannot rule out patient selection bias. Second, the treatment regimen, as well as retreatments, was decided by individual clinicians. Finally, this surveillance was conducted as a regulatory agency-mandated study, and therefore the statistical analyses were only exploratory and descriptive. In summary, this 36-month regulatory surveillance showed acceptable tolerability and effectiveness for IVT-AFL treatment administered in clinical practice for patients with nAMD in Japan. Surveillance data showed that RPE tear and other vitreo-retinal events are more likely to develop early after starting treatment, whereas increased IOP and cerebral infarction are more likely to develop relatively later, emphasising the importance of close and continuous monitoring over the long term in nAMD patients receiving IVT-AFL treatment. Methods Study design This 36-month, prospective, observational, postmarketing surveillance study in patients with nAMD was conducted at 177 sites in Japan from December 2012 to December 2018. The details of the 177 sites were 60 university hospitals, 67 general hospitals, and 50 clinics, all of which had retinal specialists. Patients were registered from December 2012 to June 2015. An electronic data capture system with a central registration method was used for the surveillance component. Study physicians registered patients, confirmed the initial injections, and entered the results at each time point up to 36 months. Observation was terminated if either of the following events occurred: (1) discontinuation of IVT-AFL treatment for any reason or (2) no visit/contact on the scheduled visit date or 4 months after the last visit. The planned number of patients to be included was 4,000, to allow for detection of at least one occurrence of an ATE, based on the reported incidence of the event (0.05%) in the VIEW trials7 at 85% probability. This surveillance was conducted in accordance with Good Post-Marketing Study Practice38 and in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation. No institutional review board (IRB) approval is formally required for postmarketing surveillance as the regulatory-imposed study in Japan. Therefore, the IRB for this entire study has not been set up. Patients and treatment Patients diagnosed with nAMD were enrolled after the investigator decided to initiate IVT-AFL treatment. Patients who were previously treated with IVT-AFL were excluded. If a patient had bilateral nAMD, the eye that received the first dose of IVT-AFL was included in the analysis. If treatment began in both eyes on the same day, the eye with the lower BCVA at baseline was selected; if BCVA in both eyes was the same, the right eye was included. Methods for diagnosis was not stipulated in the protocol and were left to the decision of treating physician, while fluorescein and indocyanine green angiographies, and optical coherence tomography (OCT) with or without OCT angiography are mainly used in Japan. After the first injection of 2 mg IVT-AFL, clinicians determined the need for repeated injections. Strict retreatment criteria were not stipulated in the protocol of the current study in a real-world clinical practice, while retreatment is commonly decided by presence of macular fluid in Japan. The inter-injection interval was at least 1 month, per manufacturer guidelines5. Outcome measures The primary outcomes were the occurrence of ADRs and of AEs. The events were coded based on Medical Dictionary for Regulatory Activities version 23.039. In accordance with the requirements from the Pharmaceutical and Medical Devices Agency in Japan, safety specifications (Supplemental Table 1), which consist of ‘important risks identified’ and ‘important potential risks’ defined by the Japan RMP, were also investigated. The other prespecified outcomes investigated were number of injections received, treatment retention rate, reasons for treatment discontinuation, duration from initial IVT-AFL treatment to ADR occurrence, BCVA, ocular findings including intraocular pressure and fundus findings, and CRT measured using optical coherence tomography at each time. Authors did not assess the low clinical records; patient data were de-identified as anonymized information before the data registration and analyses. Statistical analysis The statistical analyses were exploratory and descriptive. Categorical variables were summarised as frequency or proportion and continuous variables as fundamental statistics. Data are expressed as the mean ± standard deviation. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). Patients who received at least one IVT-AFL injection were included in the SAF. Those who had at least one available measurement of BCVA or CRT were included in the EAS. The effectiveness data were analyzed using both the observed values and the values imputed by LOCF analysis. Ethics statements This surveillance was conducted as a regulatory-mandated study in compliance with the Good Post-marketing Study Practice (GPSP) and Good Vigilance Practice of the Ministry of Health, Labour, and Welfare in Japan and is registered at ClinicalTrials.gov (NCT01756248). Informed consent was not obtained in this surveillance because the Government Authority decreed that Japanese postmarketing surveillance does not require informed consent. Supplementary Information Supplementary Information. Supplementary Information The online version contains supplementary material available at 10.1038/s41598-023-37584-1. Acknowledgements Medical writing support was provided by LiteraMed K.K. and editing support was provided by ThinkSCIENCE K.K., and the costs were borne by Bayer Yakuhin, Ltd. The study concept and design were provided by Bayer Yakuhin, Ltd. Bayer Yakuhin, Ltd. Funded, collected, analyzed, and interpreted the data, and CMIC Co., Ltd. Conducted the data management. All Participating Investigators provided care for the study patients and collected data. Author contributions Y.O., K.O., K.S., K.H. and T.S. contributed to drafting the manuscript. K.H. contributed to data acquisition. T.S. contributed to the study design and data analysis. All authors contributed to data interpretation and manuscript development. All authors read and approved the final manuscript. Data availability Availability of the data underlying this publication will be determined according to Bayer’s commitment to the EFPIA/PhRMA “Principles for responsible clinical trial data sharing”. This pertains to scope, time point, and process of data access. As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymised patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal. Data access will be granted to anonymised patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded. The available data shown above is also provided, when the request is sent to the corresponding author with appropriate reason. Competing interests This study was funded by Bayer Yakuhin, Ltd., Japan. YO has no conflict of interest regarding this study. KO, KS, KH, and TS are employees of Bayer Yakuhin, Ltd., Japan. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References 1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The right to sight: An analysis for the global burden of disease study. Lancet Glob. Health. 9(2), e144–e160, DOI: 10.1016/S2214-109X(20)30489-7 (2021). 2. Fujiwara K Prevalence and risk factors for polypoidal choroidal vasculopathy in a general Japanese population: The hisayama study Semin. Ophthalmol. 2018 33 6 813 819 10.1080/08820538.2018.1506483 30084710 3. Yasuda M Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the hisayama study Ophthalmology 2009 116 11 2135 2140 10.1016/j.ophtha.2009.04.017 19744734 4. Morizane Y Incidence and causes of visual impairment in Japan: The first nation-wide complete enumeration survey of newly certified visually impaired individuals Jpn. J. Ophthalmol. 2019 63 1 26 33 10.1007/s10384-018-0623-4 30255397 5. EYLEA (aflibercept) [package insert]. Bayer Yakuhin. Ltd., Osaka, Japan; Revised March. (2020). 6. Heier JS Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 2012 119 12 2537 2548 10.1016/j.ophtha.2012.09.006 23084240 7. Schmidt-Erfurth U Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies Ophthalmology 2014 121 1 193 201 10.1016/j.ophtha.2013.08.011 24084500 8. Eter N PERSEUS 24-month analysis: A prospective noninterventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration Graefes. Arch. Clin. Exp. Ophthalmol. 2021 259 8 2213 2223 10.1007/s00417-021-05073-8 33547967 9. Minami S Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline Sci. Rep. 2018 8 1 58 10.1038/s41598-017-18255-4 29311612 10. Japan risk management plan [Japanese]. https://www.pmda.go.jp/RMP/www/630004/fe4fcf1f-a6dc-4328-a14e-f6d90da0e564/630004_1319405A1027_004RMP.pdf, (2022). 11. Greenberg JP Aflibercept-related sterile intraocular inflammation outcomes Ophthalmol. Retina. 2019 3 9 753 759 10.1016/j.oret.2019.04.006 31153850 12. Hahn P Postmarketing analysis of aflibercept-related sterile intraocular inflammation JAMA. Ophthalmol. 2015 133 4 421 426 10.1001/jamaophthalmol.2014.5650 25590968 13. Monés J Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER Ophthalmology 2021 128 7 1050 1059 10.1016/j.ophtha.2020.11.011 33207259 14. Wickremasinghe SS Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration Ophthalmology 2008 115 11 1911 1915 10.1016/j.ophtha.2008.05.007 18672291 15. Ohji M Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : A randomized controlled trial Adv. Ther. 2020 37 3 1173 1187 10.1007/s12325-020-01236-x 32016788 16. Wong TY Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: Two-year results of the aflibercept in polypoidal choroidal vasculopathy study Am. J. Ophthalmol. 2019 204 80 89 10.1016/j.ajo.2019.02.027 30849345 17. Ebneter A Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration Sci. Rep. 2020 10 1 20256 10.1038/s41598-020-76354-1 33219242 18. Lukic M Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting Eur. J. Ophthalmol. 2021 31 4 1940 1944 10.1177/1120672120938565 32586117 19. Maruko I Iida T Saito M Nagayama D Saito K Clinical characteristics of exudative age-related macular degeneration in Japanese patients Am. J. Ophthalmol. 2007 144 1 15 22 10.1016/j.ajo.2007.03.047 17509509 20. Sho K Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics Arch. Ophthalmol. 2003 121 10 1392 1396 10.1001/archopht.121.10.1392 14557174 21. Kawasaki R The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis Ophthalmology 2010 117 5 921 927 10.1016/j.ophtha.2009.10.007 20110127 22. Kawasaki R Bauer M Bezlyak V Ogura Y Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan medical data center database Jpn. J. Ophthalmol. 2021 65 2 215 226 10.1007/s10384-020-00802-8 33420855 23. Sawada T Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration Graefes. Arch. Clin. Exp. Ophthalmol. 2021 259 5 1191 1198 10.1007/s00417-020-05005-y 33201353 24. Kaya M Öner FH Akbulut Yağci B Ataş F Öztürk T Noninfectious intraocular inflammation following intravitreal anti-vascular endothelial growth factor injection Turk. J. Ophthalmol. 2021 51 1 32 37 10.4274/tjo.galenos.2020.84042 33631912 25. Schmidt-Ott U Differing risks of occlusive retinal vasculitis with concurrent intraocular inflammation among intravitreal antivascular endothelial growth factor therapies Retina 2021 41 4 669 670 10.1097/IAE.0000000000003015 33165295 26. Hoguet A The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: A report by the American academy of ophthalmology Ophthalmology 2019 126 4 611 622 10.1016/j.ophtha.2018.11.019 30472176 27. Gabrielle PH Intraocular pressure changes and vascular endothelial growth factor inhibitor use in various retinal diseases: Long-term outcomes in routine clinical practice: Data from the fight retinal blindness! Registry. Ophthalmol. Retina. 2020 4 9 861 870 10.1016/j.oret.2020.06.020 32574830 28. Reina-Torres E VEGF as a paracrine regulator of conventional outflow facility Invest. Ophthalmol. Vis. Sci. 2017 58 3 1899 1908 10.1167/iovs.16-20779 28358962 29. Lee WA Comparative risk of arterial thromboembolic events between aflibercept and ranibizumab in patients with maculopathy: A population-based retrospective cohort study BioDrugs 2021 35 5 579 588 10.1007/s40259-021-00497-4 34495526 30. Invernizzi A Early and late retinal pigment epithelium tears after anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration Ophthalmology 2018 125 2 237 244 10.1016/j.ophtha.2017.08.039 28993010 31. Ersoz MG Karacorlu M Arf S Sayman Muslubas I Hocaoglu M Retinal pigment epithelium tears: Classification, pathogenesis, predictors, and management Surv. Ophthalmol. 2017 62 4 493 505 10.1016/j.survophthal.2017.03.004 28336128 32. Oshima Y Apte RS Nakao S Yoshida S Ishibashi T Full thickness macular hole case after intravitreal aflibercept treatment BMC. Ophthalmol. 2015 15 30 10.1186/s12886-015-0021-3 25881212 33. Liu Y Cai Q Does cataract surgery improve the progression of age-related macular degeneration? A meta-analysis J. Ophthalmol. 2020 2020 7863987 10.1155/2020/7863987 33062316 34. Barthelmes D Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration Br. J. Ophthalmol. 2016 100 12 1640 1645 10.1136/bjophthalmol-2015-308090 26994110 35. Nagai N Nonresponsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: Implications of serous pigment epithelial detachment Sci. Rep. 2016 6 29619 10.1038/srep29619 27403807 36. Conti FF 36-month evaluation of intravitreous aflibercept injection for wet age-related macular degeneration in patients previously treated with ranibizumab or bevacizumab Ophthalmic Surg. Lasers Imaging Retina 2018 49 3 179 185 10.3928/23258160-20180221-05 29554385 37. Itagaki K Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration BMC Ophthalmol. 2020 20 1 276 10.1186/s12886-020-01542-6 32650757 38. Ministry of Health, Labour and Welfare. Ministerial ordinance on good post-marketing study practice for drugs. MHLW Ordinance No. 171 of 2004. https://www.pmda.go.jp/files/000161574.pdf. 39. Medical Dictionary for Regulatory Activities, https://www.meddra.org/ (2022).